Combination chemotherapy
The invention relates to a pharmaceutical composition, a therapeutic combination product and a kit comprising a sterically hindered platinum coordination compound and a non-platinum based anti-cancer agent and a pharmaceutically-acceptable carrier or diluent; to the use thereof for the manufacture o...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
09.07.2003
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to a pharmaceutical composition, a therapeutic combination product and a kit comprising a sterically hindered platinum coordination compound and a non-platinum based anti-cancer agent and a pharmaceutically-acceptable carrier or diluent; to the use thereof for the manufacture of a medicament for inhibiting the growth of tumour cells in a human afflicted therewith; to a method of inhibiting the growth of tumour cells in a human afflicted therewith which comprises administering to such human an effective tumour cell growth inhibiting amount of such a therapeutic combination product or of a pharmaceutical composition of the invention; in particular when the sterically hindered platinum coordination compound is (SP-4-3)-(cis)-am-minedichloro-Ä2-methylpyridineÜplatinum (II), or a pro-drug thereof, and the non-platinum based anti-cancer agent is selected from Taxol Gemcitabine, Navelbine, Doxil, 5-FU and Taxotere. |
---|---|
Bibliography: | Application Number: CN20018009337 |